| Name | Title | Contact Details |
|---|
With over a century in business, MLC (formerly Mississippi Lime Company) has built a reputation on the purity of its products, commitment to research and development, and tradition of customer satisfaction. MLC operates the largest lime facility in the Americas and mines some of the purest limestone reserves in the world. The company supplies high-calcium quicklime, hydrated lime, calcium carbonate products, trucking services, and technical solutions from a diversified, reliable network of facilities in Ste. Genevieve, MO; Calera, AL; Verona, KY; Vicksburg, MS; Weirton, WV; Chester, SC; Mobile, AL; Prairie du Rocher, IL; Bridgeville, PA; as well as several distribution sites throughout the country. MLC is a privately held company that has a fully integrated system for mining limestone and manufacturing high-quality, food-grade calcium products and pulverized limestone. MLC also owns and operates a trucking and logistics subsidiary, MLC Trucking, to further support customer needs and ensure additional supply security.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.